全文获取类型
收费全文 | 154033篇 |
免费 | 33164篇 |
国内免费 | 1216篇 |
专业分类
耳鼻咽喉 | 2911篇 |
儿科学 | 4122篇 |
妇产科学 | 3381篇 |
基础医学 | 10080篇 |
口腔科学 | 5954篇 |
临床医学 | 32358篇 |
内科学 | 34992篇 |
皮肤病学 | 4062篇 |
神经病学 | 16926篇 |
特种医学 | 5687篇 |
外科学 | 26973篇 |
综合类 | 917篇 |
现状与发展 | 40篇 |
一般理论 | 59篇 |
预防医学 | 19034篇 |
眼科学 | 3356篇 |
药学 | 5220篇 |
1篇 | |
中国医学 | 60篇 |
肿瘤学 | 12280篇 |
出版年
2024年 | 765篇 |
2023年 | 5297篇 |
2022年 | 1564篇 |
2021年 | 3934篇 |
2020年 | 5912篇 |
2019年 | 3082篇 |
2018年 | 8127篇 |
2017年 | 8200篇 |
2016年 | 8836篇 |
2015年 | 9121篇 |
2014年 | 12057篇 |
2013年 | 14458篇 |
2012年 | 7558篇 |
2011年 | 7416篇 |
2010年 | 8812篇 |
2009年 | 10878篇 |
2008年 | 6829篇 |
2007年 | 6081篇 |
2006年 | 7137篇 |
2005年 | 5619篇 |
2004年 | 4729篇 |
2003年 | 4277篇 |
2002年 | 3998篇 |
2001年 | 2675篇 |
2000年 | 1960篇 |
1999年 | 2506篇 |
1998年 | 2703篇 |
1997年 | 2407篇 |
1996年 | 2442篇 |
1995年 | 2195篇 |
1994年 | 1519篇 |
1993年 | 1326篇 |
1992年 | 1280篇 |
1991年 | 1109篇 |
1990年 | 1009篇 |
1989年 | 981篇 |
1988年 | 927篇 |
1987年 | 750篇 |
1986年 | 730篇 |
1985年 | 719篇 |
1984年 | 641篇 |
1983年 | 607篇 |
1982年 | 485篇 |
1981年 | 440篇 |
1980年 | 335篇 |
1979年 | 313篇 |
1978年 | 357篇 |
1977年 | 306篇 |
1976年 | 272篇 |
1974年 | 283篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Louise Danielsson RPT MSc Susanne Rosberg RPT PhD 《Scandinavian journal of caring sciences》2015,29(3):501-509
Although depression is associated to physical discomfort, meanings of the body in depression are rarely addressed in clinical research. Drawing on the concept of the lived body, this study explores depression as an embodied phenomenon. Using a hermeneutic phenomenological approach, the analysis of narrative‐based interviews with 11 depressed adults discloses a thematic structure of an embodied process of an ambiguous striving against fading. Five subthemes elicit different dimensions of this process, interpreted as disabling or enabling: feeling estranged, feeling confined, feeling burdensome, sensing life and seeking belongingness. In relation to clinical practice, we suggest that the interdisciplinary team can focus on enhancing the enabling dimensions, for example through guided physical activities to support the patient to feel more alive, capable and connected. Moreover, we suggest that the treatment process benefits from an increased awareness of the ambiguity in the patient's struggle, acknowledging both destructive and recharging elements of the withdrawing, and the perceived conflict in‐between. 相似文献
2.
3.
4.
5.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions 下载免费PDF全文
6.
Interprofessional collaboration and communication in nursing homes: a qualitative exploration of problems in medical care for nursing home residents – study protocol 下载免费PDF全文
7.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文
8.
9.
10.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献